EGFR Molecular Classification In Vivo

H

Harbin Medical University

Status

Completed

Conditions

Molecular Imaging

Treatments

Radiation: 18F-IRS

Study type

Interventional

Funder types

Other

Identifiers

NCT03031522
14006

Details and patient eligibility

About

The investigators developed 18F-IRS as a targeted molecular imaging agent for noninvasive and repeatable detecting EGFR-activating mutational status.

Full description

The goal of investigators were to evaluate the use of 18F-IRS as a novel PET/CT radiotracer to monitor EGFR-activating mutational status and identify EGFR-TKIs benefit NSCLC patients. the investigators want to evaluated the use of 18F-IRS in lung cancer imaging in adult NSCLC patients with different EGFR mutational status of primary and metastatic cancers.

Enrollment

10 patients

Sex

All

Ages

18 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Advanced NSCLC
  • 18 years or older
  • A life expectancy of at least 12 weeks
  • Presence of a malignant lesion within the chest of at least 0.5 cm diameter as measured by computed tomography (CT)
  • Written informed consent

Exclusion criteria

  • Claustrophobia
  • Pregnancy
  • Metal implants in the thorax

Trial design

Primary purpose

Diagnostic

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

10 participants in 6 patient groups

18F-IRS : EGFR+ Patients
Experimental group
Description:
Patients in this group had EGFR-activating mutant tumors and did not receive any treatment before this study.
Treatment:
Radiation: 18F-IRS
18F-IRS :post-TKI EGFR+ Patients
Experimental group
Description:
Patients with EGFR-activating mutant tumors were receiving EGFR-TKIs during this study .
Treatment:
Radiation: 18F-IRS
18F-IRS:post-chemo EGFR+
Experimental group
Description:
18F-IRS:post-chemo EGFR+ Patients with EGFR-activating mutant tumors were receiving chemotherapy during this study.
Treatment:
Radiation: 18F-IRS
18F-IRS:EGFR wild type
Experimental group
Description:
Patients in this group had EGFR wild-type tumors and did not receive any treatment before this study.
Treatment:
Radiation: 18F-IRS
18F-IRS:post-chemo EGFR wild type
Experimental group
Description:
Patients in this group had EGFR wild-type tumors and were receiving chemotherapy during this study.
Treatment:
Radiation: 18F-IRS
18F-IRS:unknown EGFR mutational status
Experimental group
Description:
Patients without the EGFR mutational status measurement results and did not receive any treatments were classified in this group
Treatment:
Radiation: 18F-IRS

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems